MaxCyte (LSE:MXCT) Total Tax Payable : £0.00 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is MaxCyte Total Tax Payable?

MaxCyte's Total Tax Payable for the quarter that ended in Sep. 2024 was £0.00 Mil.

MaxCyte Total Tax Payable Historical Data

The historical data trend for MaxCyte's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Total Tax Payable Chart

MaxCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Tax Payable

Get a 7-Day Free Trial

MaxCyte Quarterly Data
	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Tax Payable	Get a 7-Day Free Trial															-	-	-	-	-

MaxCyte Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

MaxCyte Total Tax Payable Related Terms

Thank you for viewing the detailed overview of MaxCyte's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

MaxCyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

MXCT:USA

Address

9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850

Website

https://www.maxcyte.com

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.